Rein Therapeutics (RNTX) Other Accumulated Expenses (2018)
Rein Therapeutics (RNTX) posted quarterly Other Accumulated Expenses of $3.6 million for Q4 2018.
Rein Therapeutics (RNTX) Other Accumulated Expenses (2018) Analysis & Trends
Rein Therapeutics (RNTX) has reported Other Accumulated Expenses for 1 consecutive years, with $3.6 million the latest figure, recorded in Q4 2018.
- In Q4 2018, Other Accumulated Expenses changed N/A year-over-year to $3.6 million; the TTM figure through Dec 2018 stood at $3.6 million (changed N/A YoY), while the FY2018 annual figure was $3.6 million, changed N/A from the prior year.
- Other Accumulated Expenses was little changed at $3.6 million in Q4 2018 per RNTX's latest filing.
- Across five years, Other Accumulated Expenses topped out at $3.6 million in Q4 2018 and bottomed at $3.6 million in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Rein Therapeutics | 55.49 Mn | 55.49 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 3.64 Mn |